SLC5A2 and heart failure: Long-term studies, such as the EMPA-REG OUTCOME and CANVAS trials, have demonstrated sustained reductions in cardiovascular mortality, heart failure hospitalizations, and progression to renal disease with continued use of SGLT-2 inhibitors [19,73].